#United States #cancer detection #Lumicell #Waltham, Massachusetts #Marnie Curbow

Lumicell Welcomes Marnie Curbow as New CEO

Lumicell, Inc., a frontrunner in fluorescence-guided imaging technology dedicated to cancer detection, has officially announced the appointment of Marnie Curbow as their new Chief Executive Officer. This strategic shift comes as the company is poised to embark on a new chapter focused on growth, innovation, and the enhancement of their product offerings. With her extensive background in commercial leadership and breast oncology, Curbow is well-equipped to lead Lumicell into a future filled with opportunities for advancement.

Curbow's journey with Lumicell began in October 2025 when she joined as the Vice President of Sales. Her remarkable trajectory swiftly led to her promotion as Chief Commercial Officer, where she played a crucial role in establishing the foundational elements for the company's commercial operations. Within a remarkably short timeframe, she was integral in driving Lumicell's vision forward, showcasing her strong capability in strengthening the company’s market strategy and positioning itself favorably among its competitors.

Dr. Andrey Zarur, Chairman of the Board at Lumicell, expressed his confidence in Curbow’s leadership, stating, "Marnie has made an extraordinary impact at Lumicell in a remarkably short amount of time. Her comprehensive understanding of breast oncology, coupled with a solid record of commercial strategy development, has laid the groundwork for her ascension to CEO." This transition marks a significant milestone for Lumicell, highlighting the board's confidence in her ability to guide the organization through its next phase of growth.

Throughout her close to two decades of experience, Curbow has amassed invaluable insights across various aspects of oncology, surgery, diagnostics, and therapeutic innovations. Before her tenure with Lumicell, Curbow held the position of General Manager and VP of Sales Diagnostics for the Americas at Rhinomed, where she successfully launched a novel diagnostic platform that earned recognition, including a SPARK accelerator award from BARDA. Her unique blend of clinical and commercial expertise presents her with a distinct advantage in driving Lumicell’s technology forward and amplifying its market influence.

In a statement regarding her new role, Curbow conveyed her enthusiasm by saying, "I am deeply honored to lead Lumicell at this pivotal moment in the company's journey. The remarkable potential of our technology, combined with the strength of our dedicated team, has impressed me since I joined the company. The commitment shared by our collaborators, surgeons, and clinical partners inspires us to push the boundaries of cancer surgery further. Together, we will pursue developing real-time visualization technology, expand our commercial engagements, and enhance partnerships within the clinical community to improve patient outcomes."

Lumicell's innovative fluorescence-guided surgery system is designed to aid surgeons in identifying any residual cancer during lumpectomies. Having received FDA approval in April 2024, this technology is already being utilized across numerous hospitals in the United States. Under Curbow's guidance, Lumicell is set to strengthen its focus on advancing the adoption of pegulicianine fluorescence-guided surgery (pFGS) while also seeking to expand its current investor base and explore new applications for its technology across various solid tumor indications.

In summary, Lumicell’s decision to promote Marnie Curbow to CEO underscores its commitment to leading advancements in cancer detection and surgery. With her wealth of knowledge and strategic vision, Curbow aims to propel the company forward, fostering growth, innovation, and ultimately improving patient care through enhanced surgical techniques.

For further information on Lumicell and its pioneering technology, visit Lumicell's website or follow them on social media platforms.

About Lumicell

Lumicell, a privately-held life sciences innovator, is transforming the intraoperative detection of cancer via its real-time fluorescence imaging solutions. With a repertoire of FDA-approved technologies aimed at breast cancer treatment, the company is also nurturing its research endeavors for other solid tumor applications.